SCHEMBL6320284

SCHEMBL6320284

Cc1[nH]c2ccc(C(=O)NS(=O)(=O)c3ccc(Br)s3)cc2c1Cc1ccc2ccccc2c1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
TP53 P04637 3/20 0.38
POLB P06746 2/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321446 0.92 MAPT (0.40) MAPTMEN1KMT2ALMNAHDAC3
SCHEMBL5881972 0.87 HDAC3 (0.46) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL5882123 0.86 HDAC3 (0.47) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL6318799 0.83 MAPT (0.41) MAPTKMT2AHDAC1HDAC8HDAC6
SCHEMBL6320869 0.83 MAPT (0.41) MAPTMEN1KMT2ALMNAHDAC3
SCHEMBL6318323 0.83 MAPT (0.43) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL5884525 0.82 HDAC3 (0.43) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL5882270 0.81 PPARG (0.39) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL5882307 0.81 GPR84 (0.50) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL6320213 0.80 SCN5A (0.39) MAPTMEN1KMT2ALMNAHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A MAPT 3941/4885MEN1 3818/4885KMT2A 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.